Therefore, LCP1 has promising application prospects as a noninvasive marker of NAFLD/NASH, which is expected to replace liver biopsy to distinguish NAFLD disease stage and detect liver fibrosis degree. Here, LCP1 is linked to metabolic dysfunction-associated steatotic liver disease.